190 related articles for article (PubMed ID: 11728413)
41. Evaluation of 6-year application of the enzymatic colorimetric phenylalanine assay in the setting of neonatal screening for phenylketonuria.
Schulze A; Mayatepek E; Hoffmann GF
Clin Chim Acta; 2002 Mar; 317(1-2):27-37. PubMed ID: 11814455
[TBL] [Abstract][Full Text] [Related]
42. [Cost-benefit analysis of the early detection program for metabolic diseases in the Autonomous Basque Community].
Mugarra Bidea I; Cabasés Hita JM
Gac Sanit; 1990; 4(19):140-4. PubMed ID: 2125584
[TBL] [Abstract][Full Text] [Related]
43. [Evolution of the screening program for congenital hypothyroidism and phenylketonuria in the Sergipe State from 1995 to 2003].
Ramalho RJ; Ramalho AR; Oliveira CR; Aguiar-Oliveira MH
Arq Bras Endocrinol Metabol; 2004 Dec; 48(6):890-6. PubMed ID: 15761565
[TBL] [Abstract][Full Text] [Related]
44. Phenylketonuria detected by the neonatal screening program in Thailand.
Pangkanon S; Ratrisawadi V; Charoensiriwatana W; Techasena W; Boonpuan K; Srisomsap C; Svasti J
Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():179-81. PubMed ID: 15906730
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness of Newborn Screening for Phenylketonuria and Congenital Hypothyroidism.
Appelberg K; Sörensen L; Zetterström RH; Henriksson M; Wedell A; Levin LÅ
J Pediatr; 2023 May; 256():38-43.e3. PubMed ID: 36495999
[TBL] [Abstract][Full Text] [Related]
46. Neonatal screening for inborn errors of metabolism: update.
Seashore MR
Semin Perinatol; 1990 Dec; 14(6):431-8. PubMed ID: 2077663
[TBL] [Abstract][Full Text] [Related]
47. Genetic screening of the newborn in Australia. Results for 1978.
Pitt D; Connelly J; Francis I; Wilcken B; Brown DA; Hill G; Masters P; Tucker RG; Raby J; McFarlane J
Med J Aust; 1979 Sep; 2(5):272-3. PubMed ID: 514173
[TBL] [Abstract][Full Text] [Related]
48. Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening.
Gu X; Wang Z; Ye J; Han L; Qiu W
Ann Acad Med Singap; 2008 Dec; 37(12 Suppl):107-4. PubMed ID: 19904469
[TBL] [Abstract][Full Text] [Related]
49. Economics of tandem mass spectrometry screening of neonatal inherited disorders.
Pandor A; Eastham J; Chilcott J; Paisley S; Beverley C
Int J Technol Assess Health Care; 2006; 22(3):321-6. PubMed ID: 16984060
[TBL] [Abstract][Full Text] [Related]
50. Genetic screening of newborn in Australia. Results for 1981.
Pitt D; Connelly J; Francis I; Wilcken B; Brown DA; Robertson E; Hill G; Masters P; Raby J; McFarlane J; Bowling F; Hancock J
Med J Aust; 1983 Apr; 1(7):333-5. PubMed ID: 6835136
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of neonatal screening for congenital adrenal hyperplasia.
Honour JW; Torresani T
Horm Res; 2001; 55(4):206-11. PubMed ID: 11598376
[TBL] [Abstract][Full Text] [Related]
52. [Early diagnosis of phenylketonuria and congenital hypothyroidism. Prevention of mental retardation].
de Pediatría SC; de Neonatología R
Rev Chil Pediatr; 1988; 59(3):200-3. PubMed ID: 3251316
[No Abstract] [Full Text] [Related]
53. United Arab Emirates National Newborn Screening Programme: an evaluation 1998-2000.
al-Hosani H; Salah M; Saade D; Osman H; al-Zahid J
East Mediterr Health J; 2003 May; 9(3):324-32. PubMed ID: 15751925
[TBL] [Abstract][Full Text] [Related]
54. [Problems and results of screening tests in genetic disorders].
Knapp A
Z Arztl Fortbild (Jena); 1978 Jun; 72(11-12):535-9. PubMed ID: 676362
[No Abstract] [Full Text] [Related]
55. [Cost/benefit study of the neonatal detection of phenylketonuria and hypothyroidism].
Dhondt JL; Farriaux JP; Lebrun T; Sailly JC
Pediatrie; 1988; 43(4):345-8. PubMed ID: 3138627
[TBL] [Abstract][Full Text] [Related]
56. Screening for congenital hypothyroidism: a worldwide view of strategies.
Ford G; LaFranchi SH
Best Pract Res Clin Endocrinol Metab; 2014 Mar; 28(2):175-87. PubMed ID: 24629860
[TBL] [Abstract][Full Text] [Related]
57. Past, present and future of newborn screening in Chile.
Cornejo V; Raimann E; Cabello JF; Valiente A; Becerra C; Opazo M; Colombo M
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S301-6. PubMed ID: 20683669
[TBL] [Abstract][Full Text] [Related]
58. [Did the change of technique of screening investigations influence on improvement of test credibility in recognizing and differentiating diagnostics of hiperphenylalaninemias?].
Didycz B; Lemańska D; Słuszniak A
Przegl Lek; 2009; 66(1-2):11-3. PubMed ID: 19485249
[TBL] [Abstract][Full Text] [Related]
59. Multiplex tandem mass spectrometry assay for newborn screening of X-linked adrenoleukodystrophy, biotinidase deficiency, and galactosemia with flexibility to assay other enzyme assays and biomarkers.
Hong X; Kumar AB; Ronald Scott C; Gelb MH
Mol Genet Metab; 2018 Jun; 124(2):101-108. PubMed ID: 29680633
[TBL] [Abstract][Full Text] [Related]
60. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.
Lord J; Thomason MJ; Littlejohns P; Chalmers RA; Bain MD; Addison GM; Wilcox AH; Seymour CA
J Epidemiol Community Health; 1999 Mar; 53(3):179-86. PubMed ID: 10396496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
